Banner
  • Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Amgen is Still Strong Despite Trial Failure

Article

A late-stage trial of Amgen's drug Sensipar failed to meet the trial goal causing shares to fall, but only a little.

A late-stage trial of Amgen’s drug Sensipar failed to meet the trial goal causing shares to fall, but only a little.

In the Phase III EVOLVE trial, the drug — sold as Mimpara in Europe — was supposed to reduce the risk of death and cardiovascular problems in patients with chronic kidney disease (CKD) receiving dialysis. And while Amgen reported that patients taking Sensipar did experience a reduction, the results were not statistically significant.

"Amgen embarked on the EVOLVE trial to understand whether treating secondary [hyperparathyroidism] with Sensipar/Mimpara could positively impact the high rates of mortality and cardiovascular events among patients with CKD receiving dialysis," Sean E. Harper, MD, executive vice president of Research and Development at Amgen, said in a statement.

Click to enlarge

On Wednesday and Thursday, Amgen’s stock had climbed quickly, up 2.88% from Wednesday’s opening to midday on Thursday; however, since then share price has slowly fallen.

On Friday, after the news of the trial’s failure, the stock opened down by only 0.39% from its Thursday closing price. And it closed down by only 0.33%.

Based on the company's revenue growth and solid stock performance, among other factors, TheStreet.com, still recommends the stock as a strong buy.

The information contained in this article should not be construed as investment advice or as a solicitation to buy or sell any stock.

Read more:

Spectrum Pharma’s Long-Term Potential

Amgen Inc. Stock Buy Recommendation Reiterated

Related Videos
Victor J. Dzau, MD, gives expert advice
Victor J. Dzau, MD, gives expert advice